Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there
is no widely used definition of remission that is stringent but achievable and could be …

Background: In patients with early rheumatoid arthritis, initial combination therapies provide
earlier clinical improvement and less progression of joint damage after 1 year compared …

Objective To determine whether patients with undifferentiated arthritis (UA; inflammatory,
nontraumatic arthritis that cannot be diagnosed using current classification criteria) benefit from …

Background Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting ∼1% of
the population. The disease results from the interplay between an individual's genetic …

Objective To determine associations of methotrexate (MTX) efficacy and toxicity with single‐nucleotide
polymorphisms (SNPs) in genes coding for folate pathway enzymes in patients …

… Allaart has received speaking fees (less than $10,000) from Schering-Plough. Professors
Huizinga and Guchelaar hold a patent for the methotrexate-responsive predictive model. …

Background For patients with newly diagnosed rheumatoid arthritis, treatment aim is early,
rapid, and sustained remission. We compared the efficacy and safety of strategies initiating …

Objectives: To compare the occurrence of drug-free remission, functional ability and radiological
damage after 4 years of response-driven treatment according to four different treatment …

Background Rheumatoid arthritis is the most common autoimmune disease worldwide and
requires long-term treatment to suppress inflammation. Currently, treatment is started when …

Objective To compare clinical and radiological outcomes of four dynamic treatment strategies
in recent-onset rheumatoid arthritis (RA) after 5 years follow-up. Methods 508 patients with …